Role of ki-67 as a prognostic factor in gastrointestinal stromal tumors

World Journal of Gastroenterology

Volumn 19, Issue 4, 2013, Pages 523-527

  Belev, Borislav ^a   Brčić, Iva ^a   Prejac, Juraj ^a   Golubić, Zrna Antunac ^a   Vrbanec, Damir ^a   Božikov, Jadranka ^b   Alerić, Ivan ^a   Boban, Marko ^a   Razumović, Jasminka Jakić ^a  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Gastrointestinal stromal tumors; Ki 67; Prognostic factor; Recurrence

Indexed keywords

CD34 ANTIGEN; KI 67 ANTIGEN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN S 100; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL CYCLE; CELL PROLIFERATION; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; METASTASIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 84873666922     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i4.523     Document Type: Article

References (26)

1. Goss GA, Merriam P, Manola J Singer S, Fletcher C, Demetri G. Clinical and pathological characteristics of gastrointestinal stromal tumors (GIST). Prog Proc Am Soc Clin Oncol 2000; 19: 2000
2. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 41-47 [PMID: 7817943]
3. Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001; 8: 290-299 [PMID: 11352301 DOI: 10.1245/ aso.2001.8.4.290]
4. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000; 15: 1293-1301 [PMID: 11005253]
5. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580 [PMID: 9438854 DOI: 10.1126/science.279.5350.577]
6. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-1269 [PMID: 9588894]
7. Saul SH, Rast ML, Brooks JJ. The immunohistochemistry of gastrointestinal stromal tumors. Evidence supporting an origin from smooth muscle. Am J Surg Pathol 1987; 11: 464-473 [PMID: 3035954 DOI: 10.1097/00000478-198706000-00007]
8. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era- -a population-based study in western Sweden. Cancer 2005; 103: 821-829 [PMID: 15648083 DOI: 10.1002/cncr.20862]
9. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465 [PMID: 12094370 DOI: 10.1053/hupa.2002.123545]
10. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056 [PMID: 11287975 DOI: 10.1056/NEJM200104053441404]
11. Nilsson B, Sjölund K, Kindblom LG, Meis-Kindblom JM, Bümming P, Nilsson O, Andersson J, Ahlman H. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96: 1656-1658 [PMID: 17533389 DOI: 10.1038/ sj.bjc.6603797]
12. Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology 1999; 34: 416-424 [PMID: 10231416 DOI: 10.1046/ j.1365-2559.1999.00643.x]
13. Carrillo R, Candia A, Rodriguez-Peralto JL, Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 1997; 28: 160-165 [PMID: 9023396 DOI: 10.1016/S0046-8177(97) 90100-3]
14. Rudolph P, Gloeckner K, Parwaresch R, Harms D, Schmidt D. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study. Hum Pathol 1998; 29: 791-800 [PMID: 9712419 DOI: 10.1016/S0046-8177(98)90447-6]
15. Saund MS, Demetri GD, Ashley SW. Gastrointestinal stromal tumors (GISTs). Curr Opin Gastroenterol 2004; 20: 89-94 [PMID: 15703627 DOI: 10.1097/00001574-200403000-00007]
16. Kindblom LG, Meis-Kindblom J, Bumming P, Dimitrijevic S, Miret M, Dortok A. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST) - A population-based study of 600 cases. Ann Oncol 2003: 13 (Suppl 5): 157
17. Strickland L, Letson GD, Muro-Cacho CA. Gastrointestinal stromal tumors. Cancer Control 2008; 8: 252-261 [PMID: 11378651]
18. Gupta P, Tewari M, Shukla HS. Gastrointestinal stromal tumor. Surg Oncol 2008; 17: 129-138 [PMID: 18234489 DOI: 10.1016/j.suronc.2007.12.002]
19. Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12 [PMID: 11213830 DOI: 10.1007/s0042 80000338]
20. Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112: 608-615 [PMID: 18076015 DOI: 10.1002/cncr.23199]
21. Kwon SJ. Surgery and prognostic factors for gastric stromal tumor. World J Surg 2001; 25: 290-295 [PMID: 11343178 DOI: 10.1007/s002680020040]
22. Ohdaira H, Ohyama S, Yamaguchi T, Yanagisawa A, Kato Y, Urashima M. Ki67 and tumor size as prognostic factors of gastrointestinal stromal tumors. JMAJ 2005; 48: 586-592
23. Matsuda K, Watanabe H, Nishikura K, Endoh Y, Ajioka Y, Hitomi J. Gastric myogenic tumors Its Ki-67 mitotic count, myogenic markers, histogenesis of sarcoma and differentiation from gastric stromal tumor. Stomach and Intestine (Tokyo) 1995; 30: 1109-1124
24. Nagasako Y, Misawa K, Kohashi S, Hasegawa K, Okawa Y, Sano H, Takada A, Sato H. Evaluation of malignancy using Ki-67 labeling index for gastric stromal tumor. Gastric Cancer 2003; 6: 168-172 [PMID: 14520530 DOI: 10.1007/s10120- 003-0246-3]
25. Toquet C, Le Néel JC, Guillou L, Renaudin K, Hamy A, Heymann MF, Simon-Valla S, Le Borgne J, Maugard C, Fiche M. Elevated (& gt; or = 10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 cases. Dig Dis Sci 2002; 47: 2247-2253 [PMID: 12395897]
26. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, Yamada T, Nawata H, Tsuneyoshi M. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005; 36: 828-837 [PMID: 16084954]